在中国严重肺炎患者中,西维莱斯塔特的群体药理动力学
Xiaolin Zhang1, Huiliang Hu1, Ziran Li2
1Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Fundamental & clinical pharmacology
|February 9, 2025
概括
在重症肺炎患者中阐明了sivelestat的药理动力学. 总胆红素水平影响sivelestat清除,指导优化剂量策略,以有效治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药物新陈代谢 药物新陈代谢
背景情况:
- 西维莱斯塔特是一种中性粒细胞弹性酶抑制剂,用于重症肺炎.
- 此前,在重症肺炎患者中,sivelestat的药理动力学 (PK) 数据并不存在.
研究的目的:
- 为了确定sivelestat在中国严重肺炎患者中的PK特征.
- 为了优化这种患者群体的sivelestat剂量方案.
主要方法:
- 对接受西维莱斯塔特治疗的15名患者 (每天300-500毫克,持续5-14天) 的群体药动力学 (PPK) 分析.
- 使用超高性能液体染色学/并联质谱法测量的血药物度.
- 蒙特卡洛模拟用于评估剂量表和对目标度的共变效应 (Cmin,ss 8-12 mg/L).
主要成果:
- 一个单间模型最好地描述了sivelestat PK.
- 表面分布体积为20.88升,表面清除量 (CL) 为1.79升/小时.
- 总胆固醇 (TBIL) 被确定为影响sivelestat CL的显著共变量,建议在患有高TBIL的患者中降低剂量.
结论:
- 在重症肺炎患者中,Sivelestat CL/F的效果与健康个体相似.
- TBIL水平影响sivelestat CL/F,需要使用TBIL指导剂量.
- 基于TBIL的剂量方案为有效的sivelestat疗法提供了一种实用方法.
更多相关视频
相关概念视频
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
72
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
72
01:28Pneumonia IV: Management
288
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
288
01:30Pneumonia III: Complications and Assessment
146
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
146